



**PRESS RELEASE**  
*For Immediate Dissemination*



## **OPSENS ANNOUNCES FIRST USE OF ITS FFR PRODUCTS BY DR. NICO PIJLS**

**Quebec City, Quebec, May 20, 2015 - Opsens inc. ("Opsens" or the "Company") (TSXV:OPS) (OTCQX:OPSSF)** is pleased to announce the first use of the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR"), by Dr. Nico Pijls in Eindhoven, the Netherlands. Opsens' FFR products are designed to optimize the diagnosis and guide the treatment of patients with coronary heart disease.

"Dr. Pijls, of the Catharina Hospital in Eindhoven, the Netherlands, and Dr. Bernard De Bruyne, of the OLV Hospital in Aalst, Belgium, are the pioneers of FFR and collaborated extensively to establish FFR as the gold standard in the evaluation of coronary lesions. For that reason, we are proud to see Dr. Pijls, one of the most globally recognized cardiologists and an investigator in the FAME clinical studies on FFR, to use our products in his practice", said Claude Belleville, Vice President, Medical Devices of Opsens.

"The arrival of an optical FFR guidewire such as the OptoWire on the market is positive for interventional cardiologists and will be helpful to promote the use of FFR. It was a pleasure to use the OptoWire in several patients, some of them with complex disease. It allowed me to appreciate its reliable measurements and impressive zero drift performance during all cases performed while also acknowledging the constant connection reliability as well as its support during percutaneous coronary intervention", said Dr. Nico Pijls.

"We are confident that the positive reception of the OptoWire from key players of the FFR arena will pave the way for a successful full market launch. We will pursue our precommercialization phase by opening well recognized elite FFR centers in the coming months for further data collecting on the performance of our FFR products. We are confident in our capability to capture an interesting share of the US\$300 million FFR market which is expected to reach US\$1 billion in the medium-term", said Louis Laflamme, President and Chief Executive Officer of Opsens.

### **About Opsens Inc. ([www.opsens.com](http://www.opsens.com) or [www.opsensmedical.com](http://www.opsensmedical.com))**

Opsens focuses mainly on two large and growing markets: interventional cardiology with a focus on FFR and the industrial, oil and gas segment. In interventional cardiology, Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. In the industrial, oil & gas segment, Opsens develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.

*Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

**For further information, please contact:**

Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996

Louis Laflamme, CPA, CA, President and Chief Executive Officer, 418.682.9996